- Home
- IDN vs IMUX Comparison
IDN vs IMUX Comparison
Compare IDN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- IMUX
- Stock Information
- Founded
- IDN 1994
- IMUX 2016
- Country
- IDN United States
- IMUX United States
- Employees
- IDN N/A
- IMUX N/A
- Industry
- IDN Computer Software: Prepackaged Software
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- IDN Technology
- IMUX Health Care
- Exchange
- IDN Nasdaq
- IMUX Nasdaq
- Market Cap
- IDN 101.6M
- IMUX 92.2M
- IPO Year
- IDN 1999
- IMUX N/A
- Fundamental
- Price
- IDN $4.80
- IMUX $0.83
- Analyst Decision
- IDN Strong Buy
- IMUX Strong Buy
- Analyst Count
- IDN 3
- IMUX 5
- Target Price
- IDN $6.17
- IMUX $7.00
- AVG Volume (30 Days)
- IDN 146.3K
- IMUX 1.7M
- Earning Date
- IDN 11-12-2025
- IMUX 11-06-2025
- Dividend Yield
- IDN N/A
- IMUX N/A
- EPS Growth
- IDN N/A
- IMUX N/A
- EPS
- IDN N/A
- IMUX N/A
- Revenue
- IDN $20,662,000.00
- IMUX N/A
- Revenue This Year
- IDN $9.73
- IMUX N/A
- Revenue Next Year
- IDN $11.75
- IMUX N/A
- P/E Ratio
- IDN N/A
- IMUX N/A
- Revenue Growth
- IDN 7.12
- IMUX N/A
- 52 Week Low
- IDN $2.00
- IMUX $0.56
- 52 Week High
- IDN $6.49
- IMUX $1.73
- Technical
- Relative Strength Index (RSI)
- IDN 42.57
- IMUX 43.30
- Support Level
- IDN $4.42
- IMUX $0.78
- Resistance Level
- IDN $4.98
- IMUX $0.86
- Average True Range (ATR)
- IDN 0.23
- IMUX 0.05
- MACD
- IDN -0.02
- IMUX -0.01
- Stochastic Oscillator
- IDN 39.21
- IMUX 18.09
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.